Product Information
KESIMPTA 20 MG/0.4 ML PEN is a brand product labeled by Novartis Pharmaceuticals Corporation, priced at $24369.3694 per ML under NDC 00078100768. Its NADAC has been published 129 times since Apr 17, 2024.
Strength
20 mg/.4mL
Manufacturer
Novartis Pharmaceuticals CorporationNDC
00078100768
Classification
Brand
Dosage Form
INJECTION, SOLUTION
Route
SUBCUTANEOUS
Effective Date
9/23/2026
Active Ingredients
OFATUMUMABApproval Type
Biologic (BLA)
FDA Application
BLA125326On Market Since
10/26/2009
Pharmacological Classes
Price Statistics
The NADAC for KESIMPTA 20 MG/0.4 ML PEN has been published 129 times since Apr 17, 2024, and over the history we have for it it has risen 15.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $24369.3694 per ML |
|---|---|
| All-time high | $24459.3201 (May 13, 2026) |
| All-time low | $21064.8423 (Jul 17, 2024) |
| 52-week high | $24459.3201 |
| 52-week low | $22578.6032 |
| Median price | $22601.0045 |
| Average price | $22679.9472 |
| Largest weekly change | +8.0% (Jan 14, 2026) |
| Weeks tracked | 129 |
| Tracking since | Apr 17, 2024 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the ofatumumab market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Novartis Pharmaceuticals Corporation manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
ofatumumab market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of KESIMPTA 20 MG/0.4 ML PEN?
The current National Average Drug Acquisition Cost (NADAC) for KESIMPTA 20 MG/0.4 ML PEN, manufactured by Novartis Pharmaceuticals Corporation, is $24369.3694 per ML (NDC 00078100768), effective Sep 30, 2026.
How has the price of KESIMPTA 20 MG/0.4 ML PEN changed over time?
Over the history we have for it, the NADAC for KESIMPTA 20 MG/0.4 ML PEN has risen 15.7%. It has been tracked across 129 weekly CMS publications since Apr 17, 2024.
What are the highest and lowest recorded NADAC prices for KESIMPTA 20 MG/0.4 ML PEN?
Since Apr 17, 2024, the NADAC for KESIMPTA 20 MG/0.4 ML PEN has ranged from a low of $21064.8423 (Jul 17, 2024) to a high of $24459.3201 (May 13, 2026), with a median of $22601.0045 per ML.
Are there cheaper alternatives to KESIMPTA 20 MG/0.4 ML PEN?
No other NADAC-published product currently shares the active ingredient and strength of KESIMPTA 20 MG/0.4 ML PEN in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures KESIMPTA 20 MG/0.4 ML PEN?
KESIMPTA 20 MG/0.4 ML PEN (NDC 00078100768) is labeled by Novartis Pharmaceuticals Corporation, and CMS classifies it as a brand product.